Patil Neena M 4

Accession 0001783908-26-000005

CIK 0001232524other

Filed

Jan 20, 7:00 PM ET

Accepted

Jan 21, 8:36 PM ET

Size

7.0 KB

Accession

0001783908-26-000005

AI-generated summary of this filing

Updated Jan 22, 2026

Jazz Pharmaceuticals EVP Neena Patil Receives Award, Sells Shares

What Happened

Neena M. Patil, EVP & Chief Legal Officer of Jazz Pharmaceuticals (JAZZ), had 8,852 performance-based ordinary shares delivered to her on January 16, 2026 (award grant). On the same date, 3,275 shares were disposed to the issuer at $171.16 each, generating $560,549. The disposition represents shares withheld to satisfy tax obligations rather than an open-market sale.

Key Details

Transaction date: January 16, 2026 (reported on Form 4 filed January 21, 2026 — filed within the SEC’s two business-day window given the MLK holiday).
Award: 8,852 ordinary shares issued (value noted as $0 in the grant line because these are performance share awards vesting).
Disposition/tax withholding: 3,275 shares at $171.16 per share = $560,549 withheld/disposed to issuer.
Shares owned after transaction: Not specified in the provided filing excerpt.
Relevant footnotes:
- F1: These shares were performance awards granted March 3, 2023; performance goals were certified and vesting occurred Jan 16, 2026.
- F3: The 3,275-share disposition reflects shares withheld to satisfy the reporting person’s tax obligations.
- F2: Reporting person previously acquired small amounts via the company ESPP (116 shares on May 30, 2025 and 120 shares on Nov 28, 2025).
Transaction codes: A = Award/Grant; D = Disposition to issuer (tax withholding).

Context

This filing reflects a routine vesting of performance shares and shares withheld for taxes, not an open-market sale. Such tax-withholding dispositions are common when equity awards vest and do not necessarily signal insider sentiment about the stock.

Form 4

Period: 2026-01-16

EVP & Chief Legal Officer

Transactions

Award
Ordinary Shares
[F1][F2]
2026-01-16+8,852→ 56,614 total
Disposition to Issuer
Ordinary Shares
[F3]
2026-01-16$171.16/sh−3,275$560,549→ 53,339 total

Footnotes (3)

[F1]Represents ordinary shares of the Issuer delivered pursuant to the terms of performance share awards made to the reporting person on March 3, 2023. The performance-based vesting requirements applicable to such awards were satisfied on January 16, 2026, which represents the date on which the level of performance attained was certified.
[F2]The Reporting Person acquired 116 ordinary shares on May 30, 2025 and 120 ordinary shares on November 28, 2025 under a Section 423 Employee Stock Purchase Plan.
[F3]Shares withheld from the vesting and distribution of performance share awards to satisfy the reporting person's tax obligations.

Signature

By: /s/Paz Dizon, as attorney in fact For: Neena M Patil|2026-01-21

1 file

Jazz Pharmaceuticals plc

CIK 0001232524

Entity typeother